PCM
MDCO

Prelude Capital Management’s Medicines Co MDCO Stock Holding History

Prelude Capital Management’s Portfolio MDCO Stock Details MDCO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-4,500
Closed -$382K – 2316
2019
Q4 		$382K Buy
4,500
+4,400
+4,400% +$293K 0.01% 643
2019
Q3 		$5K Buy
+100
New +$3.99K ﹤0.01% 1573
2018
Q4 		– Sell
-40,500
Closed -$1.21M – 2349
2018
Q3 		$1.21M Sell
40,500
-100
-0.2% -$3.77K 0.07% 328
2018
Q2 		$1.49M Buy
40,600
+900
+2% +$29.2K 0.09% 230
2018
Q1 		$1.31M Buy
39,700
+3,100
+8% +$96.9K 0.1% 210
2017
Q4 		$1M Buy
+36,600
New +$1.13M 0.08% 258
2017
Q2 		– Sell
-8,800
Closed -$430K – 1983
2017
Q1 		$430K Buy
+8,800
New +$401K 0.04% 352

Other funds holding MDCO

GT
Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM

Prelude Capital Management's MDCO Position: Q1 2020 in Review

Prelude Capital Management sold out of Medicines Co (MDCO) in Q1 2020, closing a stake of 139,534 shares — an estimated $11.9M sold.

Prelude Capital Management first reported a position in MDCO in Q3 2013 and held it in 10 quarters. The position peaked at $11.9M in Q4 2019. 1 fund tracked by Wall St. Rank holds MDCO as of Q1 2020.

  • Prelude Capital Management reported no remaining Medicines Co position as of Q1 2020 after selling out during the quarter.
  • Prelude Capital Management sold 139,534 Medicines Co shares in Q1 2020, an estimated $11.9M.
  • Prelude Capital Management first reported a position in Medicines Co in Q3 2013 and held it in 10 quarters.
  • Prelude Capital Management's Medicines Co position peaked at $11.9M in Q4 2019.
  • 1 fund tracked by Wall St. Rank held Medicines Co as of Q1 2020.

Based on Prelude Capital Management's 13F filing for Q1 2020, filed 15 May 2020.